We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 957.00 | 889.06 | 1,104.00 | 6 | 11:10:20 |
From May 2019 to May 2024
By Allison Prang
The European Medicines Agency's Committee for Medicinal Products for Human Use is recommending that approval for an atopic dermatitis treatment from Regeneron Pharmaceuticals Inc. and Sanofi be extended, the companies said Friday.
The committee is recommending that the European Union approval be extended to also include people with moderate-to-severe cases of this type of dermatitis who are systemic therapy candidates and between ages 12 and 17, the companies said.
They said they expect the European Commission's final decision on the treatment's application should come in the coming months.
Write to Allison Prang at allison.prang@wsj.com
(END) Dow Jones Newswires
June 28, 2019 07:48 ET (11:48 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
